Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK government delays heart disease guidelines:

This article was originally published in Clinica

Executive Summary

The UK government has delayed issuing a national service framework for coronary heart disease because of concerns over the cost implications, reports the Health Service Journal in its September 16 edition. It is believed the Department of Health (DoH) had planned to extend the number of low and medium-risk patients monitored for coronary heart disease. However, it is concerned that this could be hugely expensive in terms of secondary care interventions and prescribing rates, according to Doncaster health authority head Dr John Radford. The framework is now expected before the end of September.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT079584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel